InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Immunome Inc.

IMNM Clue Score30
United States Fiscal year ends December CIK 0001472012 Results filed 11 Aug 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

75
Insider
Date
Role
Action
Shares
Price
Amount
Jack Higgins
11 Sep 2026
Chief Scientific Officer
Sold after exercise
13,200
$25.32
$334.22K
Isaac Barchas
12 Aug 2026
Director
Sold on a plan
11,048
$27.25
$301.06K
Isaac Barchas
11 Aug 2026
Director
Sold on a plan indirect
62,291
$26.23
$1.63M
Isaac Barchas
10 Aug 2026
Director
Sold on a plan indirect
10,125
$26.07
$263.96K
Isaac Barchas
7 Aug 2026
Director
Sold on a plan indirect
15,248
$26.06
$397.36K
Isaac Barchas
6 Aug 2026
Director
Sold on a plan indirect
20,840
$26.06
$543.09K
Kinney Horn
4 Aug 2026
Chief Business Officer
Sold after exercise
90,616
$25.09
$2.27M
Isaac Barchas
7 Jul 2026
Director
Sold on a plan indirect
16,906
$24.20
$409.13K
Kinney Horn
7 Jul 2026
Chief Business Officer
Sold after exercise
1,092
$25.00
$27.30K
Isaac Barchas
6 Jul 2026
Director
Sold on a plan indirect
83,094
$24.11
$2.00M
Isaac Barchas
2 Jul 2026
Director
Sold on a plan indirect
24,335
$23.33
$567.74K
Isaac Barchas
2 Jul 2026
Director
Sold on a plan indirect
75,665
$22.35
$1.69M
Robert Lechleider
2 Jul 2026
Chief Medical Officer
Sold after exercise
16,072
$23.44
$376.73K
Robert Lechleider
2 Jul 2026
Chief Medical Officer
Sold after exercise
16,214
$22.76
$369.03K
Robert Lechleider
2 Jul 2026
Chief Medical Officer
Sold after exercise
22,714
$21.95
$498.57K
Isaac Barchas
30 Jun 2026
Director
Sold on a plan indirect
101,050
$21.12
$2.13M
Robert Lechleider
25 Jun 2026
Chief Medical Officer
Sold after exercise
14,420
$20.66
$297.92K
Robert Lechleider
25 Jun 2026
Chief Medical Officer
Sold after exercise
40,580
$19.56
$793.74K
Max Rosett
15 Jun 2026
Chief Financial Officer
Sold after exercise
60,000
$18.23
$1.09M
Jean Jacques Bienaime
5 Jun 2026
Director
Buy
1,000
$19.27
$19.27K
Jean Jacques Bienaime
5 Jun 2026
Director
Buy
3,500
$19.46
$68.11K
Jean Jacques Bienaime
5 Jun 2026
Director
Buy
6,000
$19.48
$116.88K
Jean Jacques Bienaime
5 Jun 2026
Director
Sell
10,000
$19.41
$194.10K
Jean Jacques Bienaime
5 Jun 2026
Director
Sell
500
$19.44
$9.72K
Jean Jacques Bienaime
15 May 2026
Director
Buy
5,000
$20.70
$103.50K
Max Rosett
2 Apr 2026
Chief Financial Officer
Sold after exercise
1,344
$22.48
$30.21K
Max Rosett
2 Apr 2026
Chief Financial Officer
Sold after exercise
63,656
$21.91
$1.39M
Jack Higgins
2 Apr 2026
Chief Scientific Officer
Sold on a plan
9,438
$21.64
$204.24K
Clay B Siegall
27 Mar 2026
President and CEO
Buy
25,450
$19.67
$500.60K
Philip Wagenheim
23 Mar 2026
Director
Sell
28,200
$20.65
$582.33K
Philip Wagenheim
20 Mar 2026
Director
Sell
36,800
$20.47
$753.30K
Jean Jacques Bienaime
11 Mar 2026
Director
Buy
1,000
$21.55
$21.55K
Jean Jacques Bienaime
10 Mar 2026
Director
Buy
1,000
$22.12
$22.12K
Clay B Siegall
30 Dec 2025
President and CEO
Buy
4,729
$21.15
$100.02K
Isaac Barchas
22 Dec 2025
Director
Sold on a plan indirect
11,251
$22.34
$251.35K
Isaac Barchas
22 Dec 2025
Director
Sold on a plan indirect
371,949
$21.72
$8.08M
Philip Tsai
19 Dec 2025
Chief Technical Officer
Buy
10,000
$20.49
$204.90K
Clay B Siegall
19 Dec 2025
President and CEO
Buy
7,278
$20.48
$149.05K
Clay B Siegall
18 Dec 2025
President and CEO
Buy
46,511
$21.50
$999.99K
Jack Higgins
10 Sep 2025
Chief Scientific Officer
Exercised, kept
22,000
$1.35
$29.70K
Jean Jacques Bienaime
3 Jun 2025
Director
Buy
5,000
$9.38
$46.90K
Jack Higgins
27 Mar 2025
Chief Scientific Officer
Exercised, kept
5,200
$1.35
$7.02K
Clay B Siegall
26 Mar 2025
President and CEO
Buy
137,100
$7.29
$999.46K
Jean Jacques Bienaime
25 Mar 2025
Director
Buy
7,800
$7.78
$60.68K
Philip Tsai
24 Mar 2025
Chief Technology Officer
Buy
12,300
$8.42
$103.57K
Jean Jacques Bienaime
24 Mar 2025
Director
Buy
7,000
$8.21
$57.47K
Clay B Siegall
31 Jan 2025
President and CEO
Buy
150,000
$7.75
$1.16M
Clay B Siegall
22 Nov 2024
President and CEO
Buy
33,943
$9.78
$331.92K
Philip Tsai
21 Nov 2024
Chief Technology Officer
Buy
21,000
$9.43
$198.03K
Robert Lechleider
21 Nov 2024
Chief Medical Officer
Buy
15,805
$9.48
$149.80K
Clay B Siegall
21 Nov 2024
President and CEO
Buy
66,057
$9.54
$630.26K
Max Rosett
19 Sep 2024
Chief Financial Officer
Sold after exercise
14,380
$16.01
$230.22K
Jean Jacques Bienaime
16 Aug 2024
Director
Buy
7,000
$13.94
$97.61K
Jack Higgins
15 Aug 2024
Chief Scientific Officer
Sold after exercise
3,524
$13.93
$49.07K
Clay B Siegall
21 May 2024
President and CEO
Buy
20,434
$13.78
$281.55K
Jean Jacques Bienaime
21 May 2024
Director
Buy
2,000
$13.57
$27.14K
Clay B Siegall
20 May 2024
President and CEO
Buy
79,566
$13.91
$1.11M
Bruce Turner
2 Oct 2023
Chief Strategy Officer
Buy
42,300
$5.91
$249.99K
Clay B Siegall
2 Oct 2023
President and CEO
Buy
169,204
$5.91
$1,000.00K
Michael Rapp
13 Sep 2021
Director
Buy indirect
25,962
$19.96
$518.20K
Michael Rapp
10 Sep 2021
Director
Buy indirect
15,500
$17.85
$276.68K
Michael Rapp
9 Sep 2021
Director
Buy indirect
22,280
$18.46
$411.29K
Michael Rapp
9 Sep 2021
Director
Buy indirect
8,170
$17.44
$142.48K
Richard A Baron
18 Aug 2021
Director
Exercised, kept
2,343
$11.38
$26.66K
Michael Rapp
26 May 2021
Director
Buy indirect
2,300
$18.94
$43.56K
Michael Lefenfeld
26 May 2021
Director
Buy
1,335
$19.03
$25.41K
Purnanand D Sarma
25 May 2021
President and CEO
Buy
10,500
$18.41
$193.31K
Michael Rapp
25 May 2021
Director
Buy indirect
19,303
$18.32
$353.63K
Michael Lefenfeld
25 May 2021
Director
Buy
2,715
$18.44
$50.06K
John L Lamattina
24 May 2021
Director
Buy
5,102
$18.58
$94.80K
John L Lamattina
24 May 2021
Director
Buy
338
$18.44
$6.23K
Philip Wagenheim
24 May 2021
Director
Buy
13,500
$18.35
$247.73K
Michael Rapp
24 May 2021
Director
Buy indirect
31,895
$18.38
$586.23K
Michael Lefenfeld
24 May 2021
Director
Buy
600
$17.80
$10.68K
Michael Rapp
6 Oct 2020
Director
Buy
83,332
$12.00
$999.98K

What was left out

Form 4 filings counted 156
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 13
Sales straight out of an exercise 13
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 3,059,462
History held since 5 Oct 2020